2. February 2010 01:23
LEO Pharma today announced that in a Phase III study, PEP005 (ingenol mebutate) Gel, the company's lead candidate for the topical treatment of actinic (solar) keratosis (AK) or pre-cancerous lesions, met its primary clinical endpoint of complete clearance of AK lesions in non-head locations.
[More]
27. January 2010 03:46
Patients with gastrointestinal stromal tumours (GIST) can now take action at an earlier stage of this rare form of cancer to reduce the risk of their disease returning following surgery. Novartis Pharmaceuticals Canada announced today that Gleevec* (imatinib mesylate) has received conditional approval by Health Canada for the adjuvant (post-surgical) treatment of adult patients who are at intermediate to high risk of disease recurrence following the surgical removal of GIST.
[More]
a57f9bc6-5127-4938-868d-d0a90a40b2e9|0|.0
Posted in: Medical Condition News | Pharmaceutical News
Tags: Abdominal Pain, Adjuvant Therapy, Anemia, Angioedema, Arthralgia, Brain, Cancer, Cardiovascular Disease, Chemotherapy, Chromosome, Chronic Myeloid Leukemia, Cough, Depression, Dermatitis, Diabetes, Diarrhea, Diverticulitis, Dyspnea, Eczema, Edema, Gleevec, Headache, Hospital, Hypersensitivity, Imatinib Mesylate, Leukemia, Metastasis, Myeloid Leukemia, Nausea, Neutropenia, Oncology, Ophthalmology, Osteonecrosis, Pancreatitis, Pneumonia, Renal Failure, Sepsis, Thrombocytopenia, Thrombosis, Vomiting
25. January 2010 05:37
Allergies and asthma are a continuing health problem in most developed countries, but just how do these ailments develop over the course of a childhood? In a population-based study designed to help answer this question, researchers at the Norwegian University of Science and Technology (NTNU) found that 40 per cent - or two of five -- of nearly 5,000 two-year-olds had at least one reported allergy-related disorder. The most common symptom was wheezing, which was reported in 26 per cent of all children in the study, says Ingeborg Smidesang, a PhD candidate in the university's Faculty of Medicine, and the primary author of the study.
[More]
21. January 2010 03:37
WHAT: A new study in human cells has singled out a molecule that specifically directs immune cells to develop the capability to produce an allergic response. The signaling molecule, called thymic stromal lymphopoietin (TSLP), is key to the development of allergic diseases such as asthma, atopic dermatitis (eczema) and food allergy.
[More]
20. January 2010 00:40
Denmark-based LEO Pharma, a global leader in dermatology and critical care, today announced its official launch in the U.S. Headquartered in Parsippany, New Jersey, LEO Pharma U.S. will be one of the largest individual operations in the pharmaceutical company’s network of worldwide affiliates and is expected to contribute significantly to the company revenues in 2010.
[More]
18. January 2010 02:02
Renee Cobos, MD, a board certified dermatologist and associate professor of dermatology at the University of California, Irvine, announced today the launch of RC freshHAIR™, the first dermatologist-created hair care line that is specifically formulated to treat and prevent acne, acne rosacea, seborrhea (dandruff) and oily skin. RC freshHAIR is the newest addition to the RC Dermatology™ line of skin care products.
[More]
7. January 2010 06:37
Ceragenix Pharmaceuticals, Inc. (“Ceragenix”), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).
[More]
5. January 2010 00:55
Children of parents who refuse vaccines are nine times more likely to get chickenpox compared to fully immunized children, according to a new study led by a vaccine research team at Kaiser Permanente Colorado's Institute for Health Research.
[More]
24. December 2009 04:37
The proposed 10 percent federal tax on indoor tanning services, added to the latest U.S. Senate health care reform bill in a back-room deal over the weekend, will fall 40-50 percent short of delivering the revenue its proponents promised, according to the International Smart Tan Network (Smart Tan). The tax unfairly targets female consumers, who make up more than two-thirds of tanning clients, and would be detrimental to the thousands of women who own the majority of America's indoor tanning salons.
[More]
2. December 2009 07:55
DermaGen AB - part of the Karolinska Development dermatology and wound healing company "Pergamum" - today announced that Dermagen AB has received promising results from a clinical Phase I/IIa study. DermaGen AB is developing a novel antimicrobial peptide (AMP) treatment for atopic dermatitis. Atopic dermatitis is a chronic inflammatory skin disease where dry skin and the skin's weakened barrier function make patients susceptible to colonization by microorganisms, a triggering or exacerbating factor of the disease.
[More]
1. December 2009 08:25
Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced preliminary data for the company’s PH-10 Phase 2 clinical trial for Psoriasis as well as for its Phase 2 clinical trial for Atopic Dermatitis.
[More]
2b458cd7-15cc-49b7-8cc2-631968039f7f|0|.0
Posted in: Drug Trial News | Disease/Infection News
Tags: Atopic Dermatitis, Breast Cancer, Cancer, Dermatitis, Dermatology, Eczema, Hydrogel, Liver Cancer, Melanoma, Oncology, Psoriasis
1. December 2009 04:08
New research in the Journal of Leukocyte Biology shows the link between the nervous and immune systems and how breaking that link might lead to new treatments for a wide range of autoimmune disorders
[More]
24. November 2009 04:16
Research and Markets (http://www.researchandmarkets.com/research/0cb22f/dermatology_a_co) has announced the addition of the "Dermatology - A Colour Guide 2nd Edition" report to their offering.
[More]
23. November 2009 08:41
Ception Therapeutics, Inc., a privately held biopharmaceutical company, and Cephalon, Inc. today announced results from a Phase IIb/III clinical trial for CINQUIL(TM) (reslizumab) as a treatment for pediatric eosinophilic esophagitis (EoE). The study was designed to evaluate improvement in the co-primary endpoints of changes in esophageal eosinophil levels and clinical symptoms.
[More]
8a7b4f86-bb51-44b3-9e1d-98337ec03ffd|0|.0
Posted in: Child Health News | Drug Trial News
Tags: Antibody, Arsenic, Asthma, Biotechnology, Cell, Eczema, Exercise, Fentanyl, Monoclonal Antibody, Nervous System, Oncology, Rare Disease, Rhinitis
22. November 2009 23:51
On the skin's surface, bacteria are abundant, diverse and constant, but inflammation is undesirable. Research at the University of California, San Diego School of Medicine now shows that the normal bacteria living on the skin surface trigger a pathway that prevents excessive inflammation after injury.
[More] 
Subscribe